"ORIG3N's consumer-catalyst model in medical research supports the advancement of biomedical discoveries that will provide clinicians with new tools, knowledge and therapies to select which treatments will work best for which patients," said Smith.
Since 2014, ORIG3N has been developing breakthrough treatments and drug efficacy screening utilizing induced pluripotent stem cells (iPSCs). ORIG3N's scientific mission is to cure diseases that have degenerative cellular effects, primarily in cardiac and neurological indications. As part of this mission, they have created the world's largest and first HLA matched cell bank, called LIFECAPSULE™. ORIG3N Inc. uses LIFECAPSULE™ to better understand genetic diseases and to develop new approaches to treatment. The database now has matches for 90 percent of the U.S. population.
In addition to LIFECAPSULE™, ORIG3N Inc. has created LIFEPROFILE™ , genetic tests catered to nutrition, fitness, skin health and more to help people make more informed choices about their lifestyles.
For more information about the company, please visit: www.orig3n.com.
For more information about the LIEFCAPSULE™, please visit: www.capsule.life.
About ORIG3N, Inc.
ORIG3N is leading a transformation in the understanding and treatment of rare, genetically inherited diseases. We've established the world's largest uniformly consented cell repository to better understand the cellular and molecular foundations of disease. The cells are ever-renewing and give rise to a living database of humanity we call LIFECAPSULE™. Thousands of people have already contributed to advancing the future of healthcare—and to safeguarding their own future health. The founders are serial entrepreneurs whose previous venture, ArtusLabs, was acquired by PerkinElmer in 2011. ORIG3N can be found on Twitter, Facebook and LinkedIn.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ceo-of-leading-regenerative-medicine-company-orig3n-to-present-at-biotech-showcase-300386829.html